A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer
Interventions: DRUG: Ibrutinib|DRUG: Durvalumab
Sponsor: Pharmacyclics LLC.